Antegenes^® Prostate

Using polygenic risk score technology, this test assesses a man’s risk of developing prostate cancer in the next 10 years so that preventative treatment can be sought at a much earlier stage.

Enquire now Buy now

Genetic testing for prostate cancer risk

Antegenes^® Prostate assesses an individual’s risk of developing prostate cancer based on the technology of polygenic risk scores. It uses data from 121 genome-wide single nucleotide polymorphisms (SNPs) to help guide cancer screening and risk-reduction measures for prostate cancer.

The test is recommended for men between the ages of 40 and 70 who do not have symptoms of prostate cancer and/or have been diagnosed with the cancer.

Why choose Antegenes^® Prostate?

Analyses a wider genetic profile other than the ‘known’ genes associated with an increased risk of prostate cancer.
Enables your customers to access screening earlier than the NHS National Screening programme recommends.
Provides a clinical assessment of prostate cancer risk for those who do not know their family medical history.

Diseases tested►Close tab

Prostate cancer

Genes tested for►Close tab

It uses 121 prostate cancer-related SNPs to estimate personalised risk scores.

Test results►Close tab

A personalised results report will be sent to the customer and made available to their clinician* (upon the customers consent)**.

There are two possible result outcomes from this test:

A lower risk test result
An increased risk test result

Every person taking the test will be sent a clinical support video explaining what their test results mean and the next steps to take.

In the case of an increased risk result, guidance is provided on what the customer should do next. This may include talking to their clinician about earlier screening options to help reduce the risk of developing prostate cancer or seeking treatment earlier to help prevent mortality from the disease.

The results report will include the following:

Polygenic risk score: A score derived from thousands of genetic variants.
Personal risk: This shows an individual’s risk of developing the cancer tested for over the next 10 years, compared to someone of their age in the general population.
General population comparison: A number showing the average risk that someone of a similar age in the general population has of developing prostate cancer.
Relative risk: A number which compares your risk to that of the general population.

No personal medical guidance is provided in the test result. This should be obtained from the customer’s clinician.

*Results reports are only sent to the customers clinician when a test is organised through a GP/clinic/hospital.
**No results information is shared with an employer or insurance provider.

Ordering information►Close tab

Who can order this test from Everything Genetic? Healthcare providers, employers and individuals.

Turnaround time: 4 weeks from the receipt of a sample in our laboratory.

Preferred specimen: Non-invasive simple saliva sample using Oragene OG-610.

Alternative specimen collection: None.

Delivery information: Test kits will be sent out by using a Royal Mail Tracked service, unless otherwise arranged.

Pre and post test clinical support►Close tab

Pre and post-test clinical support is a mandatory requirement for all customers taking the test.

Pre-test support is provided through a clinically guided informational video which explains:

What the test is for
Why customers should take the test
What it does and doesn’t test for
What the possible results are from taking the test

Following the test, customers will be provided a further clinically guided information video, depending on their level of risk.

For both pre and post-test clinical support, the customer has the option to arrange a telephone call with our Medical Director, Dr James Mackay.

Clinical description►Close tab

The risk of developing hereditary prostate cancer is estimated at around 5%. However, there are over 160 prostate cancer risk-associated SNPs that have been identified through genetic studies. These can be used to determine the carrier status of genetic variants that affect a customer’s individual risk. These are combined into a polygenic risk assessment, along with the 10-year probability of developing the disease.

Individual risk is put into context with the population background data, estimating the genetic risks of individuals of the same sex, age and nationality.

Antegenes^® Prostate is a registered CE-marked medical device (IVD) developed by the Antegenes Medical Laboratory.

Limitations:

Antegenes^® Prostate is not used to diagnose prostate cancer.
An increased risk estimated by this test does not mean that an individual will develop prostate cancer during their lifetime. Nor does a lower risk mean that the probability of developing the disease is zero.
The test does not assess the risk of family and relatives, i.e. polygenic risk score-based disease risks may not be transmitted directly from parents to children.
Antegenes^® Prostate does not analyse rare pathogenic mutations in genes that significantly increase the risk of prostate cancer, such as BRCA1, BRCA2, ATM, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6 and others.
The test is based on the most up-to-date scientific data, which may be supplemented and changed in the future as additional information becomes available. The field of genetics is constantly evolving, which may lead to changes in risk assessments over time, as well as changes in test selection recommendations and clinical recommendations based on test results.
Different polygenic risk scores that predict risks of the same trait may provide different estimates. This is due to differences in genetic variants included in the models and their weights.
The results of this test should be applied in context with other relevant clinical data, and other risk factors.